Navigation Links
Tafamidis: Approval denotes proven added benefit
Date:4/5/2012

This release is available in German.

Tafamidis meglumine (trade name: Vyndaqel) was approved in November 2011 for the treatment of transthyretin amyloidosis in adults. This rare disorder ("orphan disease") is caused by a defective gene and is associated with progressive nerve damage (neurological degeneration) that tafamidis is supposed to delay. According to 35a SGB (Social Code Book) V, an added benefit is regarded as proven if a drug for a rare disease - known as an orphan drug - has been approved. The German Institute for Quality and Efficiency in Health Care (IQWiG) has assessed tafamidis at the request of the Federal Joint Committee (G-BA).

The scientific assessment by IQWiG has produced a hint of a positive effect of tafamidis on neurological degeneration.

Tafamidis compared with "best supportive care"

Transthyretin (TTR) is formed in the liver and is involved in the transport of the thyroid hormone, thyroxine. Mutations in the TTR gene can lead to transthyretin amyloidosis in which there is a build-up of an abnormally modified protein in various organs. These insoluble deposits result in a chronic disease that is associated with the progressive degeneration of the nervous system (polyneuropathy). In most patients, the transthyretin gene is modified at a particular site and this mutation is called "Val30Met". Tafamidis meglumine is approved for the treatment of transthyretin amyloidosis in adult patients with stage 1 neurological disorders to delay the progression of degeneration of peripheral nerves, e.g. in the arms and legs.

Treatment with tafamidis combined with "best supportive care" was compared with "best supportive care" alone. The term "best supportive care" means the therapy that provides the patient with the best possible individually optimized supportive treatment to alleviate symptoms and improve the quality of life, for instance the treatment of pain in polyneuropathy with other drugs (e.g. amitriptyline, gabapentin).

Positive effect in neurological disorders only limited

Only one of the two relevant studies (Fx-005) provided reliable data - and only for patients with a particular genetic defect (Val30Met). The second study (Fx1A-201) in adults with different genetic defects was not controlled, i.e. here the effect of tafamidis was not directly compared with another treatment. It remains unclear how the results of the reliable study can be applied to the patients with genetic defects other than Val30Met.

Assessment of the study data according to the methods of IQWiG produced a hint of a positive effect of tafamidis in respect of the progression of nerve damage. However the effect was only minor.

With regard to other patient-relevant outcomes (other symptoms and side effects, mortality, quality of life), the Institute was unable to identify any further statistically significant advantages or disadvantages of tafamidis compared with the comparator treatment.

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessment conducted by the G-BA. After publication of the manufacturer's dossier and its assessment by IQWiG, the G-BA initiates a formal commenting procedure which provides further information and can result in a change to the benefit assessment. The G-BA then decides on the extent of the added benefit, thus completing the early benefit assessment.


'/>"/>

Contact: Anna-Sabine Ernst
presse@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. Neuralstems NSI-189 trial in major depressive disorder receives FDA approval to advance to Phase Ib
2. FDA Revokes Approval of Avastin for Breast Cancer
3. St. Michaels echocardiology lab awarded international seal of approval
4. Mayo Clinic receives FDA approval for ovarian and breast cancer vaccines
5. Pioneering stem cell bandage receives approval for clinical trial
6. FDA predictability a top concern for medtech firms; EU preferred for product approval
7. New Hepatitis C Drugs Close to Gaining FDA Approval
8. New Hepatitis C Drug Close to Gaining FDA Approval
9. Sanofi Pasteur announces FDA approval of menactra meningococcal conjugate vaccine indication for infants
10. FDA approval of brain aneurysm device gives Jefferson neurosurgeons another life-saving tool
11. Novel immunotherapy drug receives FDA approval for the treatment of metastatic melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... ... 19, 2017 , ... DMG Productions, producers of the award ... an upcoming episode, slated to air fourth quarter 2017. Check your local listings ... a company committed to supporting dentistry using the most technologically advanced restorative materials ...
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... Curl Keeper® ... of NaturallyCurly.com® The Curl Leaders, Editors’ Choice 2017 Award for the second year in ... for hair stylists and curlies alike was voted Best Moisturizer for Type 2 Wavies ...
(Date:8/19/2017)... ... August 19, 2017 , ... “Congratulations! It's A Boy! God’s Gift: ... both their parents and God. “Congratulations! It's A Boy! God’s Gift: A Story of ... from Long Island, New York. , Published by Christian Faith Publishing, Dale Anthony and ...
(Date:8/18/2017)... NY (PRWEB) , ... August 18, 2017 , ... ... of “Vision & Hearing” campaign, advocating for active, healthy lifestyles and highlighting the ... available for individuals with hearing impairments and shares the latest innovations in hearing ...
(Date:8/18/2017)... VA (PRWEB) , ... August 18, 2017 , ... ... asset protection services and financial consultations to communities throughout the greater DC region, ... K9 with the goal of rescuing local animals and training them to be ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... Aug. 2, 2017 CaryRx, a next-generation full-service pharmacy, ... service for patients in the Washington D.C. ... pharmacy by providing delivery of medications through the convenience of ... delivery or delivered within one hour to any location in ... to bring this invaluable service to Washington D.C. ...
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
(Date:7/26/2017)... 2017  Radium Medical Aesthetics, a leading medical aesthetic clinic in ... by effectively addressing several skin conditions from the inside. ... and more fragile. The skin becomes more transparent due to the ... harmful UV rays from the sun contributes to aging skin, causing ... ...
Breaking Medicine Technology: